Sites Key to Successfully Advancing Decentralized Clinical Trials

As it enthusiastically embraces aspects of decentralized clinical trials (DCTs), the drug and device development industry is running the risk of “leapfrogging over [study] sites and forgetting about them as a key stakeholder” in the enterprise, says Mary Costello, Head of the Site and Investigator Network, Medable.